维普中文期刊产品整合服务
12篇 您的检索式:作者名="Grahnquist"
    题名 作者 年代 出处 被引量
1Efficacy and safety of granulocyte, monocyte/macrophage adsorptive in pediatric ulcerative colitis显示文摘AIM: To investigate efficacy and safety for granulocyte, monocyte apheresis in a population of pediatric patients with ulcerative colitis.METHODS: The ADAPT study was a prospective, openlabel, multicenter study in pediatric patients with moderate, active ulcerative colitis with pediatric ulcerative colitis activity index(PUCAI) of 35-64. Patients received one weekly apheresis with Adacolumn granulocyte, monocyte/macrophage adsorptive(GMA) apheresis over 5 consecutive weeks, optionally followed by up to 3 additional apheresis treatments over 3 consecutive weeks. The primary endpoint was the change in mean PUCAI between baseline and week 12; the secondary endpoint was improvement in PUCAI categorized as(Significant Improvement, PUCAI decrease of ≥ 35), Moderate Improvement(PUCAI decrease of 20 < 35), Small Improvement(PUCAI decrease of 10 < 20) or No change(PUCAI decrease of < 10). RESULTS: Twenty-five patients(mean age 13.5 years; mean weight 47.7 kg) were enrolled. In the intention-to-treat set(ITT), the mean value for PUCAI improvement was 22.3 [95%CI: 12.9-31.6; n = 21]. In the per-protocol(PP) set, the mean improvement was 36.3 [95%CI: 31.4-41.1; n = 8]. Significant Improvement was recorded for 9 out of 20 patients(45%); 5 out of 20 patients(25%) had Moderate Improvement and one patient(5%) had No Change in PUCAI score at week 12. In the PP set, six out of eight patients(75%) showed Significant Improvement; and in two out of eight patients(25%) Moderate Improvement was recorded. The endoscopic activity index(EAI) decreased by 3 points on average. Seven(7) out of 21(33%) patients in ITT and 4 out of 8(50%) patients in PP have used steroids during the clinical investigation. The mean steroid dosage for these patients in the ITT set decreased from a mean 12.4 mg to 10 mg daily on average from Baseline to week 12.CONCLUSION: Adacolumn; GMA apheresis treatment was effective in pediatric patients with moderate active Ulcerative Colitis. No new safety signals were reported. The present data contribute to considering GMA apheresis as a therapeutic option in pediatric patients having failed first line therapy.Tarja Ruuska Peter Küster Lena Grahnquist Fredrik Lindgren Anne Vibeke Wewer 2016World Journal of Gastroenterology2016,22,17:3
2Increasing Incidence of Paediatric Inflammatory Bowel Disease in Northern Stockholm County, 2002–2007显示文摘Petter Malmborg Lena Grahnquist Johan Lindholm Scott Montgomery Hans Hildebrand 2013Journal of Pediatric Gastroenterology and Nutrition2013,,1:2
3Early development of human gastric H,K-adenosine triphosphatase显示文摘Grahnquist L Ruuska T Finkel Y 2000J Pediatr Gast roenterol Nutr2000,30,5:1
4Early development of human gastric H, K-adenosine triphosphatase 显示文摘Grahnquist L Ruuska T Finkel Y 2000J Pediatr Gastroenterol Nutr2000,30,5:1
5Changing pattern of paediatric inflammatory bowel disease in northern Stockhom 1990-2001 显示文摘Hildebrand H Finkel Y Grahnquist L 2003Gut2003,52,:1
6Neonatal Proteus meningoet eephalitis ease report显示文摘GRAHNQUIST L LUNDBERG B TULLUS K 1992APMIS1992,100,8:1
7Cesarean section and the risk of pediatric C rohn' s disease显示文摘Malmborg P Bahmanyar S Grahnquist L 2012Inflamm Bowel Dis2012,18,4:1
8Cesarean section and the risk of pediatric Crohn' s disease显示文摘Malmborg P Bahmanyar S Grahnquist L 0,,04:1
9Regulation of K^+ transport in the rat distal colon via angiotensin Ⅱ subtype receptors and K^+-pathways显示文摘Grahnquist L Chen M Gerasev A 2001Acta Physiol Scand2001,171,2:1
10Changing pattern of paediatric inflammatory bowel disease in northern Stockbom 1990-2001 显示文摘Hildebrand H Finkel Y Grahnquist L 2003Gut2003,52,10:1
11Cesarean section and the risk of pediatrie Crohn's disease显示文摘Malmborg P Bahmanyar S Grahnquist L 2012Inflamm Bowel Dis2012,18,4:1
12Early development of human gastric H, K-adenosine triphosphatase 显示文摘Grahnquist L Ruuska T Finkel Y 2000Journal of Pediatric Gastroenterology and Nutrition2000,30,5:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费